|
Office Locations:
|
333 N. Alabama Street Suite 350
Indianapolis, IN 46204
Phone: 317-429-0140
Fax: 317-759-2819
| | |
|
|
|
Information Technology
Life Sciences & Healthcare
Medical Device
|
|
|
Lilly Ventures is the venture capital arm of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. The fund's primary goal is to facilitate the success of companies in Lilly's areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest: Biotechnology, targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a robust pipeline; Healthcare IT, targeting investments in start-up companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model; and Medical Technology, targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics. The fund also has a sister fund, Lilly Asian Ventures, which was established in 2007, and has a geographic focus on the emerging life science businesses of east and south Asia, particularly China and India.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|